

Alaska Medical Assistance DUR Committee Meeting Minutes

Friday, January 21st, 2022

Meeting was held telephonically due to COVID-19. 1:00 PM

Drug Utilization Review Committee Attendees

Members Present	Non Members Present
Erin Narus, PharmD (DHSS)	Umang Patel, PharmD (Magellan)
Charles Semling, PharmD (DHSS)	Ryan Ruggles, PharmD, MSHI (Magellan)
Charles Ryan, MD	
Robert Carlson, MD	
Barb Piromalli, DO	
Jonathon Harrison, PharmD	Members Absent
Keri McCutcheon, RPh	Dr. Heath McAnally, MD
Matthew Begay-Bruno	

Call to order at 1 PM.

Review of minutes from September 2021

Charles Semling asked the committee if they had any changes to the minutes.

Motion to approve by Charles Ryan

Second by Barb Piromalli.

Minutes approved.

Review of Agenda

Charles Semling went over the agenda for the committee members.

Overview of Medicaid Prescription and Cost Trends

Charles Semling went through the detail of the program trend snapshot. The year over year spend had increased.

The top classes have pretty much stayed in the same order.

The top 25 drugs by total claims was shown for Q3 of 2020 and 2021. This demonstrated that the drugs is similar. The top drugs by reimbursement showed some shifts as well. The top drugs by net net for the same comparison range was then reviewed for the committee. The Preferred Drug List's effect on driving the net net cost list was mentioned.

Prospective Drug Utilization Review/Clinical Topic Areas

New Prescription Medications (Interim PA List – 6 month review)

Interim PA list was short for this meeting. Charles Semling presented the logic for these medications and conditions that they treat. Pilocarpine was mentioned as an interesting use. The committee commented that the Oxycodone/APAP 10/300/5ml could be lowered from a suspend 2 to a suspend 1. The committee agreed that the list seemed reasonable. Charles Semling also commented on removing Valtoco and Nayzilam from the suspend list.

Keri McCutcheon moved to approve
Second by Charles Ryan.
No committee opposition.

New Prior Authorizations, Quantity Limits, Edits

Sphingosine 1-phosphate receptor modulators (siponimod, ponesimod, and ozanimod) criteria was presented. The committee questioned the requirement for one disease state to have “The patient does not have severe sleep apnea.” and not the other indication. Charles Semling explained that it is a drug specific criterion. He stated that he could add in on the Multiple Sclerosis Diagnosis another line that would read “If the request is for Ozanimod, the patient does not have severe sleep apnea.”

Keri McCutcheon moved to approve with the addition.
Charles Ryan seconded.
No committee opposition.

Opzelura criteria was presented. The committee was concerned about the toxicity of the drug, and that looking at use in the future.

Keri McCutcheon moved to approve.
Charles Ryan seconded.
No committee opposition.

Inhaled Prostacyclin Mimetic, Tyvaso, and Ventavis criteria was presented.

Charles Ryan moved to approve.
Barb Piromalli seconded.
No committee opposition.

Benlysta criteria was presented.

The committee commented on the redundancy of having the test for antibodies.

Keri McCutcheon moved to approve.
Charles Ryan seconded.
No committee opposition.

Reclast and Zometa criteria was presented.

Charles Semling commented he would add underlines to indicate the need for one of the diagnoses in each spot.

Charles Ryan moved to approve with underlining.
Barb Piromalli seconded.
No committee opposition.

Prolia and Xgeva criteria was presented.

Charles Semling commented that he would underline to highlight the need for one diagnosis in the criteria. Dosing differences were commented on, and it was explained that it's dosed for indication and release rate. The committee commented on removing from denial criteria "The member is not receiving routine dental exams due to the risk of osteonecrosis of the jaw (ONJ).". Charles Semling commented that it was also on the Reclast criteria, and he would remove it from both.

Charles Ryan moved to approve with changes.

Matthew Begay-Bruno seconded.

No committee opposition.

Eucrisa Criteria was presented, and the state recommended removing the criteria.

The committee discussed the quantity limit and were in favor of retaining the quantity limit.

Charles Ryan moved to approve the removal.

Robert Carlson seconded.

Interleukin-5 Inhibitors Nucala, Cinqair and Fasentra was presented, and only the new indication for Nasal Polyps was discussed.

Keri McCutcheon moved to approve the removal.

Charles Ryan seconded.

Opioid Report

Charles Semling presented the opioid use tables.

The committee discussed briefly that some of the decrease in trends could be a result in fewer elective surgeries being performed. It was noted that there was a decrease in all MME categories. The theme across all tables was an improvement over time. Potentiator utilization showed a good decrease.

Data showing new starts for opiates during a 3-month period was shown. Then the breakdown to show patients that ended up being chronic users of opioids and the number that stopped at 3 months and 6 months.

ICD-10 Compliance report for opioids was presented to the committee and noted the increase in trend. ICD-10 Compliance report for Stimulants was presented. It was noted that most pharmacies are doing well. Charles Semling then presented a request to letter the pharmacies re-notifying them of the requirement and to request an improvement before making a system change to not allow an override. The importance of communicating the diagnosis was noted. The committee discussed altering the letter to demonstrate the pharmacies that are doing well and give the pharmacies that receive the letter an idea of how poorly they are doing.

Keri McCutcheon moved to approve the sending of the letter with the changes discussed.

Charles Ryan seconded.

FDA UPDATES

Safety Reports

FDA Warns that getting alcohol-based hand sanitizer in the eyes can cause serious injury.

Diabetes patients on Statins

Data was discussed regarding the use of statins in diabetic patients. The committee noted that it appeared that the numbers looked decent compared to other sources on percentages of diabetics on a statin.

Post meeting comments

Charles Semling opened the opportunity for the public to be able to talk for 3 minutes and asked if there was anyone in attendance. Malan Paquette took the opportunity to discuss open vacancies across Alaska for boards and commissions and encouraged the committee to engage with their professional contacts to help to fill those positions.

End of Public Meeting

Adjournment 3:06 p.m.

Next meeting date March 18th, 2022.